EP1129711A3 - L'acide pinolénique contre le diabète - Google Patents

L'acide pinolénique contre le diabète Download PDF

Info

Publication number
EP1129711A3
EP1129711A3 EP01200471A EP01200471A EP1129711A3 EP 1129711 A3 EP1129711 A3 EP 1129711A3 EP 01200471 A EP01200471 A EP 01200471A EP 01200471 A EP01200471 A EP 01200471A EP 1129711 A3 EP1129711 A3 EP 1129711A3
Authority
EP
European Patent Office
Prior art keywords
pinolenic acid
acid against
against diabetes
pinolenic
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP01200471A
Other languages
German (de)
English (en)
Other versions
EP1129711B1 (fr
EP1129711A2 (fr
Inventor
Louise Brown
Frederick William Cain
Martin Richard Green
Julia Sarah Rogers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever PLC
Unilever NV
Original Assignee
Unilever PLC
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever PLC, Unilever NV filed Critical Unilever PLC
Priority to EP01200471A priority Critical patent/EP1129711B1/fr
Publication of EP1129711A2 publication Critical patent/EP1129711A2/fr
Publication of EP1129711A3 publication Critical patent/EP1129711A3/fr
Application granted granted Critical
Publication of EP1129711B1 publication Critical patent/EP1129711B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP01200471A 2000-02-24 2001-02-12 L'acide pinolénique contre le diabète Expired - Lifetime EP1129711B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP01200471A EP1129711B1 (fr) 2000-02-24 2001-02-12 L'acide pinolénique contre le diabète

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00301440 2000-02-24
EP00301440 2000-02-24
EP01200471A EP1129711B1 (fr) 2000-02-24 2001-02-12 L'acide pinolénique contre le diabète

Publications (3)

Publication Number Publication Date
EP1129711A2 EP1129711A2 (fr) 2001-09-05
EP1129711A3 true EP1129711A3 (fr) 2001-09-12
EP1129711B1 EP1129711B1 (fr) 2004-01-28

Family

ID=31197762

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01200471A Expired - Lifetime EP1129711B1 (fr) 2000-02-24 2001-02-12 L'acide pinolénique contre le diabète

Country Status (4)

Country Link
EP (1) EP1129711B1 (fr)
AT (1) ATE258435T1 (fr)
DE (1) DE60101859T2 (fr)
ES (1) ES2213666T3 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1302114A3 (fr) * 2001-10-16 2004-01-14 Loders Croklaan B.V. Mélanges pour stimuler l'assimilation du glucose
GB0311081D0 (en) 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
WO2005018632A1 (fr) 2003-08-18 2005-03-03 Btg International Limited Traitement d'etats neurodegeneratifs
JP2007509624A (ja) * 2003-10-30 2007-04-19 リピッド ニュートリション ベスローテン フェンノートシャップ 松葉からの抽出物を含む食品
GB0514463D0 (en) * 2005-01-31 2005-08-17 Loders Croklaan Bv Use of pinolenic acid
GB0504362D0 (en) 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
EP2090172A1 (fr) * 2007-10-29 2009-08-19 Lipid Nutrition B.V. Composition de pâte
EP2214519B1 (fr) * 2007-10-29 2011-06-22 Lipid Nutrition B.V. Composition de soupe ou de sauce et son procédé de production
US10744070B2 (en) 2015-06-19 2020-08-18 University Of Southern California Enteral fast access tract platform system
WO2016205754A1 (fr) 2015-06-19 2016-12-22 University Of Southern California Compositions et procédés pour l'administration de nutriments modifiés
US12599544B2 (en) 2024-05-09 2026-04-14 Alsteni Medical, Inc. Intraoral gastrointestinal access device and related methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6158536A (ja) * 1984-08-31 1986-03-25 Nippon Oil & Fats Co Ltd 栄養組成物
DE19503993A1 (de) * 1995-02-08 1996-08-14 Johann Friedrich Dr Med Desaga Verwendung eines Produktes zur enteralen Versorgung mit Lebensmittelinhaltsstoffen oder Arzneimittelinhaltsstoffen
FR2756465A1 (fr) * 1996-12-03 1998-06-05 D A Noste Additif alimentaire, composition cosmetique et medicament a base d'huile de graines de pin
WO1998032455A1 (fr) * 1997-01-27 1998-07-30 Ling Ji Extrait d'aiguilles de pin et son utilisation
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
EP1088552A1 (fr) * 1999-09-30 2001-04-04 Unilever N.V. Compositions, contenant de l'acide pinolénique et leur utilisation dans le domaine de la santé

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6158536A (ja) * 1984-08-31 1986-03-25 Nippon Oil & Fats Co Ltd 栄養組成物
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
DE19503993A1 (de) * 1995-02-08 1996-08-14 Johann Friedrich Dr Med Desaga Verwendung eines Produktes zur enteralen Versorgung mit Lebensmittelinhaltsstoffen oder Arzneimittelinhaltsstoffen
FR2756465A1 (fr) * 1996-12-03 1998-06-05 D A Noste Additif alimentaire, composition cosmetique et medicament a base d'huile de graines de pin
WO1998032455A1 (fr) * 1997-01-27 1998-07-30 Ling Ji Extrait d'aiguilles de pin et son utilisation
EP1013278A1 (fr) * 1997-01-27 2000-06-28 Ling Ji Extrait d'aiguilles de pin et son utilisation
EP1088552A1 (fr) * 1999-09-30 2001-04-04 Unilever N.V. Compositions, contenant de l'acide pinolénique et leur utilisation dans le domaine de la santé

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 010, no. 219 (C - 363) 31 July 1986 (1986-07-31) *

Also Published As

Publication number Publication date
ATE258435T1 (de) 2004-02-15
ES2213666T3 (es) 2004-09-01
DE60101859D1 (de) 2004-03-04
EP1129711B1 (fr) 2004-01-28
DE60101859T2 (de) 2004-12-30
EP1129711A2 (fr) 2001-09-05

Similar Documents

Publication Publication Date Title
PL2162019T3 (pl) Kompozycja lipidowa do poprawy czynności mózgu
EP1474991A4 (fr) Aliments contenant des matieres grasses, enrichis en ubiquinol
EP1129711A3 (fr) L'acide pinolénique contre le diabète
WO2004078166A3 (fr) Utilisation d'acides gras omega-3 dans le traitement de personnes diabetiques
WO2001058271A8 (fr) Supplements nutritionnels pour animaux de compagnie ages
CA2399039A1 (fr) Gel de l'acide hyaluronique, son procede de production et produit medical le contenant
ATE323480T1 (de) Zusammensetzungen, enthaltend pinolensäure sowie deren verwendung zur gesundheitserhaltung
WO2000040705A3 (fr) Gene desaturase humain et ses utilisations
WO2002015938A8 (fr) Nouvelle formulation de testosterone decanoate pour le traitement de l'homme
ATE406882T1 (de) Zusammensetzungen zur normalisierung des zirkadianen rythmus
EP1158977A4 (fr) Procede et composition se rapportant a l'administration d'un inhibiteur de la cyclo-oxygenase-2
AU6843000A (en) High lipid diet
WO1999066914A3 (fr) Composition neuroprotectrice utilisee dans la prevention et/ou le traitement de modifications du systeme nerveux et du comportement induites par des etats anxieux ou depressifs
WO2003074043A1 (fr) Agents destines a elever la temperature corporelle
EP1645197A4 (fr) Exhausteur de gout corse contenant un produit de decomposition d'acide gras hautement insature a longue chaine ou contenant un extrait de celui-ci
HUP0200511A3 (en) Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
CA2353451A1 (fr) Procede permettant d'ameliorer la fermete du gras et la qualite de la viande chez des animaux
PL1799204T3 (pl) Kompozycja zawierająca kwasy tłuszczowe omega-3 i omega-6
NZ598529A (en) Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
WO2000056325A3 (fr) Solution d'ibuprofene
BRPI0506456A (pt) composição de alimento com sabor
WO2004085364A1 (fr) Procédé pour stabiliser de l'acide 1,4-dihydroxy-2-naphtoïque
EP1161948A3 (fr) Composition pharmaceutique et nutritive pour traiter l'oedème cérébral
WO2003037375A1 (fr) Substance d'induction de cytokine et instrument d'induction de cytokine
WO2007019275A3 (fr) Esters de phytosterol

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17P Request for examination filed

Effective date: 20010830

AKX Designation fees paid

Free format text: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

17Q First examination report despatched

Effective date: 20030115

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 27/12 B

Ipc: 7A 61P 9/12 B

Ipc: 7A 61P 27/02 B

Ipc: 7A 61P 25/02 B

Ipc: 7A 61K 31/20 A

Ipc: 7A 61P 3/10 B

Ipc: 7A 61K 35/78 B

Ipc: 7A 61P 13/12 B

Ipc: 7A 61P 17/02 B

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040128

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040128

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040128

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040128

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040128

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040128

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040128

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040128

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040212

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040212

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040228

REF Corresponds to:

Ref document number: 60101859

Country of ref document: DE

Date of ref document: 20040304

Kind code of ref document: P

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: UNILEVER PLC

Owner name: UNILEVER N.V.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040428

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040428

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040428

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: UNILEVER N.V.

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2213666

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20041029

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040628

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20140227

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20140226

Year of fee payment: 14

Ref country code: FR

Payment date: 20140220

Year of fee payment: 14

Ref country code: IT

Payment date: 20140225

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20140227

Year of fee payment: 14

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60101859

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20150212

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20151030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150901

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150302

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20160330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150213